Global Biologics, Cell and Gene Legal Summit 2023

Practical Regulatory, Legal and Commercial Strategies for the Biologic Marketplace Across Europe, the US and Asia

Download the Agenda
Brussels, Belgium (BEL)
13-14 June, 2023

“This Global Biologics Cell and Gene Conference has been an extremely good forum for sharing views and address hop topics within the industry, I am glad I could spend the two days last week in Brussels with such a group of specialists. I am certainly looking forward to the next edition.”

Emmanuel Gougé, Partner, Pinsent Masons

WHY ATTEND

With many biologic patents set to lose exclusivity in 2023 a patent cliff is on the way. Generic, biosimilar and innovator biopharma companies are in different positions and will need to react differently to these changing market circumstances. Additionally, the face of biologics is changing with and increasing number of gene therapy and antibody-drug conjugate options adding to and sometimes taking the place of “naked antibodies”. The Global Biologics, Cell and Gene Summit is perfect place to address these changes with leading industry experts from across the IP, Regulatory and Commercial fields.

Highlights include:

  1. Understanding how the UPC will shape the future patent landscape for biologic products
  2. Discover the latest global perspective on the situation for biologics/biosimilars in Europe, US, and Asia.
  3. Understand the latest regulatory framework for biologic products.
  4. Learn the latest trends within the biologics marketplace with the commercial, regulatory and IP updates on Cell and Gene products.
100+
Attendees
30+
Executive Speaking Faculty
6
Individually Curated Roundtable Discussions
3
Regional Biologic Marketplaces

HOW TO GET INVOLVED

ATTEND AS A DELEGATE

Join us to network with colleagues and gain insights from industry experts on how you can create new innovative commercial and legal strategies, overcome market barriers, and take advantage of the growing opportunities in the biologic marketspace.

REGISTER FOR 2023

PARTNER WITH US

Based on your objectives we can create bespoke packages especially for you.

From presenting your experience on stage to hosting networking drinks. You can partner with us to showcase your brand and make valuable new connections. Opportunities predominently lie in 3 main categories: Thought Leadership, Branding, and Networking.

Discuss your objectives with Duncan Henderson, Senior Commercial Partnerships Manager; [email protected] or register your your interest in sponsorship here: 

REGISTER INTEREST IN SPONSORSHIP

AUDIENCE BREAKDOWN

50%
Industry In-House
40%
Law Firms
10%
Vendors/CDMOs

Industry In-House

Law Firms

Vendors/CDMOs

FIND OUT MORE ABOUT THIS YEARS SUMMIT

We're excited to be returning to Brussels this year to uncover the latest global standings in the European, US, and Asian for biologics/biosimilars marketplaces. We've compiled an agenda of some top in-house and private practice legal representatives with sessions exploring: 

  • The latest legal regulatory framework
  • The biologics patent landscape
  • The effective commercialisation of biologic products

Fill out this quick form to access the full agenda

 

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick the "YES" box.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.


2023 Global Biologics, Cell and Gene Legal Summit

GLOBAL BIOLOGICS, CELL & GENE LEGAL SUMMIT 2023 COMMUNITY

From our advisory board and speaking faculty to our media and strategic partners, our series wouldn't be possible without the contributions of our esteemed community of in-house legal representatives, trademark/patent private practice lawyers and legal press

2023 Speakers

 

Poopak Banky

Senior IP Counsel (IP Lead Cell & Gene)
Novartis

Poopak Banky

Senior IP Counsel (IP Lead Cell & Gene)
Novartis

Poopak Banky

Senior IP Counsel (IP Lead Cell & Gene)
Novartis
 

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB
 

Rob Aerts

Senior Patent Counsel Europe
ADM

Rob Aerts

Senior Patent Counsel Europe
ADM

Rob Aerts

Senior Patent Counsel Europe
ADM
 

Nicolas Pourbaix

Associate General Counsel
Amgen

Nicolas Pourbaix

Associate General Counsel
Amgen

Nicolas Pourbaix

Associate General Counsel
Amgen
 

Georgia Gavriilidou

Associate General Counsel
Amgen

Georgia is currently holding the position of the Associate General Counsel (Executive Director) at Amgen, coordinating the legal strategy at a  European Level on legal regulatory topics (including medicinal devices, pharmacovigilance, combination products, etc), market access and litigation. In her former role at the EMA, she was the lead lawyer on the implementation of major pharmaceutical legislation including the advanced therapies legislation and pharmacovigilance legislation.

Georgia Gavriilidou

Associate General Counsel
Amgen

Georgia Gavriilidou

Associate General Counsel
Amgen

Georgia is currently holding the position of the Associate General Counsel (Executive Director) at Amgen, coordinating the legal strategy at a  European Level on legal regulatory topics (including medicinal devices, pharmacovigilance, combination products, etc), market access and litigation. In her former role at the EMA, she was the lead lawyer on the implementation of major pharmaceutical legislation including the advanced therapies legislation and pharmacovigilance legislation. She has also served as chief legal adviser on a wide array of pharmaceutical issues relating to fixed-dose combination medicinal products, orphan and pediatric medicinal products, parallel distribution, invented names and validation/pre-authorization issues. Her experience also covers counseling clients on life-cycle management of bio/pharma medicinal products, including the maximization of IP regulatory rights and representing clients on legal strategy before the National / EU Authorities, the UK and EU Courts (for EMA and clients). 

 

Suzanne Renes

European Patent Attorney
Sanofi

Suzanne graduated Cum Laude from Amsterdam University College in 2015 with a BSc in Biomedical Sciences. In 2016 she graduated from University College London with an MSc in Pharmaceutical Formulation and Entrepreneurship. She is a qualified Dutch and European Patent Attorney that started her career in the Pharma team at NLO in 2018. Since January 2022 she has been employed in the Ablynx team of Sanofi in Ghent, where she has been working as a patent attorney specializing in immunoglobulin single variable domains (camelid-derived VHH).

Suzanne Renes

European Patent Attorney
Sanofi

Suzanne Renes

European Patent Attorney
Sanofi

Suzanne graduated Cum Laude from Amsterdam University College in 2015 with a BSc in Biomedical Sciences. In 2016 she graduated from University College London with an MSc in Pharmaceutical Formulation and Entrepreneurship. She is a qualified Dutch and European Patent Attorney that started her career in the Pharma team at NLO in 2018. Since January 2022 she has been employed in the Ablynx team of Sanofi in Ghent, where she has been working as a patent attorney specializing in immunoglobulin single variable domains (camelid-derived VHH). In her free time, she enjoys learning new languages, playing badminton and dancing salsa.

 

Tamaris Bucher

Principal Patent Attorney
Novartis

Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.

She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.

Tamaris Bucher

Principal Patent Attorney
Novartis

Tamaris Bucher

Principal Patent Attorney
Novartis

Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.

She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.

Tamaris is both a registered European Patent Attorney and Swiss Patent Attorney. Additionally, she has a background in Australian patent law, having completed a Master of Industrial Property at the University of Technology, Sydney.

 

Katherine Helm

Partner
Dechert

Katherine Helm

Partner
Dechert

Katherine Helm

Partner
Dechert
 

Kaushal Joshi

Senor Director Legal, IP and Product Portfolio
Kashiv Biosciences

Kaushal Joshi

Senor Director Legal, IP and Product Portfolio
Kashiv Biosciences

Kaushal Joshi

Senor Director Legal, IP and Product Portfolio
Kashiv Biosciences
 

Michael Swifta

Director of Intellectual Property Policy
EFPIA

Michael Swifta

Director of Intellectual Property Policy
EFPIA

Michael Swifta

Director of Intellectual Property Policy
EFPIA
 

Eva Temkin

Partner
King and Spalding (Ex FDA Deputy Director, Therapeutic Biologics and Biosimilars)

Eva Temkin

Partner
King and Spalding (Ex FDA Deputy Director, Therapeutic Biologics and Biosimilars)

Eva Temkin

Partner
King and Spalding (Ex FDA Deputy Director, Therapeutic Biologics and Biosimilars)
 

Kirsten Broeckers

Vice President & Head legal Affairs EMEA
Novartis Gene Therapies GmbH

Kirsten Broeckers

Vice President & Head legal Affairs EMEA
Novartis Gene Therapies GmbH

Kirsten Broeckers

Vice President & Head legal Affairs EMEA
Novartis Gene Therapies GmbH
 

Adrian Spillmann

Director of Intellectual Property
Valneva

Adrian Spillmann is Director of Corporate Intellectual Property for the Valneva group (a European biotech company focusing on vaccines) in Vienna, Austria, and specializes in patent and trademark prosecution, patent and trademark enforcement, patent drafting, patent portfolio management, in house patent counseling, patent monetization and intellectual property transactions in biotechnology and pharmaceuticals and other life science projects.

Adrian Spillmann

Director of Intellectual Property
Valneva

Adrian Spillmann

Director of Intellectual Property
Valneva

Adrian Spillmann is Director of Corporate Intellectual Property for the Valneva group (a European biotech company focusing on vaccines) in Vienna, Austria, and specializes in patent and trademark prosecution, patent and trademark enforcement, patent drafting, patent portfolio management, in house patent counseling, patent monetization and intellectual property transactions in biotechnology and pharmaceuticals and other life science projects.

His areas of expertise include protection of prophylactics, therapeutics, and diagnostics for infectious diseases, immunological disorders, cancerous diseases, neurodegenerative disorders and metabolic disorders, vaccine technologies, antibody technologies, production of biological and chemical compounds, new medical uses, and formulations of known compounds.

After earning his Ph.D. at the University of Zurich, Switzerland, Adrian was a Consultant at Deloitte, followed by a 7-year stay in various positions in the patent department at Novartis. Furthermore, Adrian was Senior Patent Attorney at Ablynx, an antibody company in Belgium, for three years.

Adrian is a European and Swiss-registered patent attorney and received his LLM from the University of Law in London.

 

Sharada Devarasetty

Head of Biopharmaceuticals Patents
Sandoz

Sharada has spent the last decade building global IP strategies to launch biosimilars.  She started her career in the US with the patent litigation group at Proskauer Rose, participating in several ITC litigations in addition to her district court docket.  In 2012, she moved to Boehringer Ingelheim to begin her career in the then-new and exciting biosimilars market.  There she helped build strategies for most of the first wave biosimilar, in addition to advising her client how to prepare for global biosimilar litigation.  More recently, she leads the biosimilar IP team at Sandoz, a global l

Sharada Devarasetty

Head of Biopharmaceuticals Patents
Sandoz

Sharada Devarasetty

Head of Biopharmaceuticals Patents
Sandoz

Sharada has spent the last decade building global IP strategies to launch biosimilars.  She started her career in the US with the patent litigation group at Proskauer Rose, participating in several ITC litigations in addition to her district court docket.  In 2012, she moved to Boehringer Ingelheim to begin her career in the then-new and exciting biosimilars market.  There she helped build strategies for most of the first wave biosimilar, in addition to advising her client how to prepare for global biosimilar litigation.  More recently, she leads the biosimilar IP team at Sandoz, a global leader in biosimilars, for the next wave of launches.

 

Hilary Pioro

Senior Patent Counsel
Polpharma Biologics

Hilary Pioro

Senior Patent Counsel
Polpharma Biologics

Hilary Pioro

Senior Patent Counsel
Polpharma Biologics
 

Chad Shear

Principal
Fish & Richardson (USA)

Chad is a principal in the firm’s San Diego office and is the go-to patent litigator for numerous multinational life sciences companies — including Gilead, GSK, iCeutica, Iroko, Coherus Biosciences and Dainippon Sumitomo Pharma — whose marquee products deliver billions of dollars in annual revenues. He draws on his litigation experience, extensive network of scientific and business experts, and detailed knowledge of his clients’ companies to provide strategic legal counsel on a wide range of business matters.

Chad Shear

Principal
Fish & Richardson (USA)

Chad Shear

Principal
Fish & Richardson (USA)

Chad is a principal in the firm’s San Diego office and is the go-to patent litigator for numerous multinational life sciences companies — including Gilead, GSK, iCeutica, Iroko, Coherus Biosciences and Dainippon Sumitomo Pharma — whose marquee products deliver billions of dollars in annual revenues. He draws on his litigation experience, extensive network of scientific and business experts, and detailed knowledge of his clients’ companies to provide strategic legal counsel on a wide range of business matters. With extensive global experience, including serving as lead attorney in complex patent proceedings, trials and appeals across Asia, Europe, North America, and Australia, Chad has proven to be a results-focused, hands-on leader known for assembling and managing effective, collaborative teams across multiple time zones, firms, and languages.

 

Martina Hufnal

Patent Trial Lawyer
Fish and Richardson

Martina Hufnal

Patent Trial Lawyer
Fish and Richardson

Martina Hufnal

Patent Trial Lawyer
Fish and Richardson
 

Claudia Milbradt

Partner
Clifford Chance

Claudia heads the German IP practice and the German Tech Group of Clifford Chance. She is also a member of the leadership team of Clifford Chance's Global Tech Group. Claudia has advised clients in the field of intellectual property since 1999. She specializes in patent and trademark litigation and strategic advice for cross-border IP litigations. Claudia has significant experience in technology transfer, patent license agreements as well as research and development projects.

Claudia Milbradt

Partner
Clifford Chance

Claudia Milbradt

Partner
Clifford Chance

Claudia heads the German IP practice and the German Tech Group of Clifford Chance. She is also a member of the leadership team of Clifford Chance's Global Tech Group. Claudia has advised clients in the field of intellectual property since 1999. She specializes in patent and trademark litigation and strategic advice for cross-border IP litigations. Claudia has significant experience in technology transfer, patent license agreements as well as research and development projects.

 

Blaz Visnar

Deputy Head of Unit, DG Competition
European Commission

Blaz Visnar

Deputy Head of Unit, DG Competition
European Commission

Blaz Visnar

Deputy Head of Unit, DG Competition
European Commission
 

Kelly Knaapen Arts

Senior Director of IP, European Patent Attorney
Merus

Kelly is Senior Director, European Patents and IP Operations at Merus. She has a Master’s degree in Biomedical Sciences and started her career as European patent attorney in private practice. In 2019 she joined Merus, where she is responsible for the operation of the IP department, directs the IP strategy, and advances Merus’ patent portfolio relating to multispecific antibodies.

Kelly Knaapen Arts

Senior Director of IP, European Patent Attorney
Merus

Kelly Knaapen Arts

Senior Director of IP, European Patent Attorney
Merus

Kelly is Senior Director, European Patents and IP Operations at Merus. She has a Master’s degree in Biomedical Sciences and started her career as European patent attorney in private practice. In 2019 she joined Merus, where she is responsible for the operation of the IP department, directs the IP strategy, and advances Merus’ patent portfolio relating to multispecific antibodies. Working together with several outside counsel and collaboration partners, her focus is on establishing a strong IP position and freedom to operate for Merus’ key platform technology and clinical and pre-clinical products to support Merus’ mission to close in on cancer.  

 

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

 

Sherry Yao

Partner
King & Wood Mallesons

Sherry Yao

Partner
King & Wood Mallesons

Sherry Yao

Partner
King & Wood Mallesons
 

Seng Koon Lim

IP Leader
Chugai Pharmabody Research

Seng Koon Lim

IP Leader
Chugai Pharmabody Research

Seng Koon Lim

IP Leader
Chugai Pharmabody Research
 

Jimmy Nicholls

Partner
J A Kemp

Jimmy Nicholls

Partner
J A Kemp

Jimmy Nicholls

Partner
J A Kemp
 

Alberto Giummarra

Director EU Government Affairs
GSK

Alberto Giummarra

Director EU Government Affairs
GSK

Alberto Giummarra

Director EU Government Affairs
GSK
 

Emmanuel Gougé

Partner
Pinsent Masons

Emmanuel Gougé is a renowned counsel and litigator in IP law, with a strong focus on patents, trade secrets and trademarks. Emmanuel has been involved in a range of multi-jurisdictional IP matters. His practice focuses mainly on electronics, automotive, aerospace, life sciences, and medical devices. Emmanuel has been involved in a wide range of cross-border litigations and has played an instrumental role in advising clients on multi-jurisdictional matters.

Emmanuel Gougé

Partner
Pinsent Masons

Emmanuel Gougé

Partner
Pinsent Masons

Emmanuel Gougé is a renowned counsel and litigator in IP law, with a strong focus on patents, trade secrets and trademarks. Emmanuel has been involved in a range of multi-jurisdictional IP matters. His practice focuses mainly on electronics, automotive, aerospace, life sciences, and medical devices. Emmanuel has been involved in a wide range of cross-border litigations and has played an instrumental role in advising clients on multi-jurisdictional matters.

 

Krishna Kakkaiyadi

Senior Associate
Pinsent Masons

Krishna Kakkaiyadi

Senior Associate
Pinsent Masons

Krishna Kakkaiyadi

Senior Associate
Pinsent Masons
 

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr.

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr. Wong also has extensive experience with Inter Partes Review, Post Grant Review, intellectual property counseling, pharmaceutical regulatory counseling, pre-suit investigations, licensing, and due diligence.

Mr. Wong has his BS with high distinction in Chemistry and his BS in Biochemistry from the University of Illinois Urbana-Champaign and his JD, cum laude, from the University of Notre Dame. Mr. Wong is currently an elected member of the Venable Board, is an Advisory Board Member for the Center for Biosimilars, is Treasurer, Executive Committee member, and Board Trustee for the Foundation for Advancement of Diversity in IP Law (FADIPL) and serves as faculty for the National Institute of Trial Advocacy (NITA) and Lawline.

 

Gordon Gao

International Partner
King & Wood Mallesons

Gordon Gao specialises in intellectual property disputes involving patents, trade secrets, trademarks, copyrights, abuse of intellectual property rights, royalty rates for standard-essential patents and end-of-patent-life litigation for pharmaceutical products.

Gordon Gao

International Partner
King & Wood Mallesons

Gordon Gao

International Partner
King & Wood Mallesons

Gordon Gao specialises in intellectual property disputes involving patents, trade secrets, trademarks, copyrights, abuse of intellectual property rights, royalty rates for standard-essential patents and end-of-patent-life litigation for pharmaceutical products.


Dr. Gao serves clients across a wide range of sectors including pharmaceuticals, medical devices, semiconductors and communications. With profound expertise and experience in handling litigation cases, he assists clients in developing the most appropriate strategies and plans to protect their rights and interests. Dr. Gao has advised major multinational enterprises on intellectual property strategies in many high-profile cases. Knowing well the court practices and procedures of all the major courts and arbitral institutions, he provides clients with constructive and practical advice throughout the life cycle of a project.

 

Jon Singer

Principal
Fish & Richardson

Jon is a principal in the firm’s San Diego office and heads the life sciences litigation practice. He appears regularly as lead counsel in his matters and handles all aspects of litigation, including leading jury and bench trials, trying cases to administrative and arbitration panels and conducting briefing and arguments before the U.S. Courts of Appeals and the PTAB. Jon is annually named one of the nation’s finest life sciences trial attorneys and is an expert in proceedings under the Hatch-Waxman Act.

Jon Singer

Principal
Fish & Richardson

Jon Singer

Principal
Fish & Richardson

Jon is a principal in the firm’s San Diego office and heads the life sciences litigation practice. He appears regularly as lead counsel in his matters and handles all aspects of litigation, including leading jury and bench trials, trying cases to administrative and arbitration panels and conducting briefing and arguments before the U.S. Courts of Appeals and the PTAB. Jon is annually named one of the nation’s finest life sciences trial attorneys and is an expert in proceedings under the Hatch-Waxman Act. His clients consistently praise his innovative and ground-breaking work and over the past two decades, he has successfully handled dozens of cases covering all aspects of the life sciences.

 

Elizabeth Anne Wright

Partner
Cooley

Elizabeth Anne Wright

Partner
Cooley

Elizabeth Anne Wright

Partner
Cooley
 

Jonas Koponen

Partner
Cooley

Jonas Koponen

Partner
Cooley

Jonas Koponen

Partner
Cooley
 

Stephen Reese

Partner
Clifford Chance

Stephen Reese

Partner
Clifford Chance

Stephen Reese

Partner
Clifford Chance

Partner with Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

Global IP Hub Advisory Board

Author:

Fredrik Fredh

Intellectual Property Counsel
iff

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Fredrik Fredh

Intellectual Property Counsel
iff

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Author:

Lorenz Kallenbach

Senior Corporate Patent Counsel (Director)
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Lorenz Kallenbach

Senior Corporate Patent Counsel (Director)
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Author:

Stephan Kutik

Director, Intellectual Property
Genevant Sciences GmbH

Stephan Kutik

Director, Intellectual Property
Genevant Sciences GmbH

Author:

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Author:

Nicolas Pourbaix

Associate General Counsel
Amgen

Nicolas Pourbaix

Associate General Counsel
Amgen

Author:

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB

Author:

Alexandra Moulson

VP Development
Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.

She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.

Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.

Alexandra Moulson

VP Development
Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.

She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.

Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.

Author:

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech

Author:

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Author:

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

JOIN US IN BRUSSELS THIS YEAR

Venue

Le Louise Hotel Brussels, Avenue de la Toison d’Or, 40, B-1050 Brussels

This year's summit will be taking place at Le Louise Hotel Brussels 

Click here to claim a discounted room rate: EUR220 per night inc VAT and service
City tax excluded (EUR 4.24 per night per bedroom)

Discounted rate availble until 2nd June 2023

BOOK YOUR PLACE TODAY

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Saturday, May 20, 2023 to Thursday, June 15, 2023
Industry In-House
€1599
Standard pricing
Saturday, May 20, 2023 to Friday, June 16, 2023
Private Law Practices
€2399
Standard pricing
Saturday, May 20, 2023 to Friday, June 16, 2023
Consultants/Vendors
€2899
Standard pricing
Preparing registration...

Global Biologics Cell & Gene Legal Summit Testimonials

Resources

Download Resource

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us